Table 1. Demographic and Clinical Characteristics of the Overall Cohort by Race and Ethnicitya.
| Characteristic | Overall cohort (N = 50 411) | Race and ethnicity | ||
|---|---|---|---|---|
| Black (n = 6912) | Latinx (n = 3973) | White (n = 39 526) | ||
| Cancer type | ||||
| Advanced non–small cell lung cancer | 20 961 (41.6) | 2496 (36.1) | 993 (25.0) | 17 472 (44.2) |
| Metastatic breast cancer | 9912 (19.7) | 1503 (21.7) | 1047 (26.4) | 7362 (18.6) |
| Metastatic colorectal cancer | 10 596 (21.0) | 1488 (21.5) | 1222 (30.8) | 7886 (20.0) |
| Multiple myeloma | 4348 (8.6) | 938 (13.6) | 379 (9.5) | 3031 (7.7) |
| Metastatic pancreatic cancer | 4594 (9.1) | 487 (7.0) | 332 (8.4) | 3775 (9.6) |
| Age group, yb | ||||
| 19-34 | 431 (0.9) | 85 (1.2) | 81 (2.0) | 265 (0.7) |
| 35-49 | 3952 (7.8) | 669 (9.7) | 576 (14.5) | 2707 (6.8) |
| 50-64 | 15 996 (31.7) | 2649 (38.3) | 1370 (34.5) | 11 977 (30.3) |
| 65-74 | 16 507 (32.7) | 2133 (30.9) | 1128 (28.4) | 13 246 (33.5) |
| ≥75 | 13 525 (26.8) | 1376 (19.9) | 818 (20.6) | 11 331 (28.7) |
| Genderc | ||||
| Female | 28 878 (57.3) | 4214 (61.0) | 2376 (59.8) | 22 288 (56.4) |
| Male | 21 533 (42.7) | 2698 (39.0) | 1597 (40.2) | 17 238 (43.6) |
| Practice typec | ||||
| Academic | 12 501 (24.8) | 1618 (23.4) | 727 (18.3) | 10 156 (25.7) |
| Community oncology | 37 910 (75.2) | 5294 (76.6) | 3246 (81.7) | 29 370 (74.3) |
| Regionc | ||||
| Midwest | 6340 (12.6) | 447 (6.5) | 133 (3.3) | 5760 (14.6) |
| Northeast | 7319 (14.5) | 675 (9.8) | 448 (11.3) | 6196 (15.7) |
| South | 18 674 (37.0) | 3937 (57.0) | 1092 (27.5) | 13 645 (34.5) |
| West | 4300 (8.5) | 172 (2.5) | 864 (21.7) | 3264 (8.3) |
| Unknownd | 13 778 (27.3) | 1681 (24.3) | 1436 (36.1) | 10 661 (27.0) |
| ECOG performance statuse | ||||
| 0 | 15 359 (30.5) | 2104 (30.4) | 1358 (34.2) | 11 897 (30.1) |
| 1 | 18 183 (36.1) | 2418 (35.0) | 1192 (30.0) | 14 573 (36.9) |
| ≥2 | 7639 (15.2) | 1159 (16.8) | 484 (12.2) | 5996 (15.2) |
| Not documented | 9230 (18.3) | 1231 (17.8) | 939 (23.6) | 7060 (17.9) |
| Year of diagnosis | ||||
| 2017-2019 | 30 311 (60.1) | 4001 (57.9) | 2287 (57.6) | 24 023 (60.8) |
| 2020-2022 | 20 100 (39.9) | 2911 (42.1) | 1686 (42.4) | 15 503 (39.2) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
Data are expressed as No. (%) of patients unless stated otherwise. Percentages are column percentages for specified groups. Racial and ethnic groups were mutually exclusive.
Age was defined at clinical diagnosis.
Gender, practice type, and region reflect the most recent electronic health record (EHR)–documented value. Gender values likely reflect a patient’s sex assigned at birth; however, it is unknown whether these values represent sex assigned at birth or gender identity or were self- or clinician reported. These values varied by practice at individual clinical sites and the limitations of the EHR software used. Region was missing for a small proportion of patients for whom the state of residence was not recorded in the physician’s records. For deidentification reasons, region was nulled out for all patients treated at an academic practice, even if they were also treated at a community practice or in a few low-population states for all patients (Alaska, Montana, North Dakota, South Dakota, Vermont, or Wyoming), any territories outside of the 50 states, the District of Columbia, and Puerto Rico.
Includes Puerto Rico and the District of Columbia.
ECOG performance status reflects the value closest to the start of first-line therapy, per oncologist-defined rule-based line of therapy.